Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Axsome Therapeutics Inc (AXSM) Ord Shares

Sell:$76.86 Buy:$77.15 Change: $2.81 (3.52%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$76.86
Buy:$77.15
Change: $2.81 (3.52%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$76.86
Buy:$77.15
Change: $2.81 (3.52%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Contact details

Address:
22 CORTLANDT STREET, 16TH FLOOR
NEW YORK
10007
United States
Telephone:
+1 (212) 3323241
Website:
axsome.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AXSM
ISIN:
US05464T1043
Market cap:
$2.97 billion
Shares in issue:
37.34 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Herriot Tabuteau
    Chairman of the Board, President, Chief Executive Officer, Founder
  • Nick Pizzie
    Chief Financial Officer
  • Mark Jacobson
    Chief Operating Officer
  • Amanda Jones
    Senior Vice President - Clinical Research
  • Cedric O'Gorman
    Senior Vice President - Clinical Development and Medical Affairs
  • David Marek
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.